[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100616025":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":29,"responsibleParty":130,"collaborators":18,"id":132,"slug":133,"hasResults":134,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":18,"eligibilityCriteria":138,"healthyVolunteers":134,"sex":139,"minAge":140,"maxAge":18,"enrollmentInfo":141,"targetDuration":18,"studyType":144,"phases":145,"briefSummary":147,"conditions":148,"keywords":158,"overallStatus":32,"whyStopped":18,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":170},{"fullName":5,"class":6},"Neomorph, Inc","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Single agent NEO-811 dose escalation","EXPERIMENTAL","NEO-811",[13],"Drug: NEO-811",[15],{"type":16,"name":11,"description":11,"armGroupLabels":17,"otherNames":18},"DRUG",[9],null,[20],{"name":21,"affiliation":5,"role":22},"Klaus Wagner, MD, PhD","STUDY_DIRECTOR",[24],{"name":25,"role":26,"phone":27,"phoneExt":18,"email":28},"Sara Weymer","CONTACT","+1 858-428-9800","clinicaltrials@neomorph.com",[30,44,53,63,73,83,91,101,111,120],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":18},"NEO-811 Los Angeles Site","RECRUITING","Duarte","California","91010","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-117.97729,34.13945,{"lat":42,"lon":41},{"facility":45,"status":32,"city":46,"state":34,"zip":47,"country":36,"countryCode":37,"cosmosGeoPoint":48,"geoPoint":52,"contacts":18},"NEO-811 San Diego Site","San Diego","92037",{"type":39,"coordinates":49},[50,51],-117.16472,32.71571,{"lat":51,"lon":50},{"facility":54,"status":32,"city":55,"state":56,"zip":57,"country":36,"countryCode":37,"cosmosGeoPoint":58,"geoPoint":62,"contacts":18},"NEO-811 Chicago Site","Zion","Illinois","60099",{"type":39,"coordinates":59},[60,61],-87.83285,42.44613,{"lat":61,"lon":60},{"facility":64,"status":32,"city":65,"state":66,"zip":67,"country":36,"countryCode":37,"cosmosGeoPoint":68,"geoPoint":72,"contacts":18},"NEO-811 Grand Rapids Site","Grand Rapids","Michigan","49503",{"type":39,"coordinates":69},[70,71],-85.66809,42.96336,{"lat":71,"lon":70},{"facility":74,"status":32,"city":75,"state":76,"zip":77,"country":36,"countryCode":37,"cosmosGeoPoint":78,"geoPoint":82,"contacts":18},"NEO-811 Long Island Site","Lake Success","New York","11042",{"type":39,"coordinates":79},[80,81],-73.71763,40.77066,{"lat":81,"lon":80},{"facility":84,"status":32,"city":76,"state":76,"zip":85,"country":36,"countryCode":37,"cosmosGeoPoint":86,"geoPoint":90,"contacts":18},"NEO-811 NYC Site","10065",{"type":39,"coordinates":87},[88,89],-74.00597,40.71427,{"lat":89,"lon":88},{"facility":92,"status":32,"city":93,"state":94,"zip":95,"country":36,"countryCode":37,"cosmosGeoPoint":96,"geoPoint":100,"contacts":18},"NEO-811 South Carolina Site","Myrtle Beach","South Carolina","29572",{"type":39,"coordinates":97},[98,99],-78.88669,33.68906,{"lat":99,"lon":98},{"facility":102,"status":32,"city":103,"state":104,"zip":105,"country":36,"countryCode":37,"cosmosGeoPoint":106,"geoPoint":110,"contacts":18},"NEO-811 Dallas Site","Dallas","Texas","75039",{"type":39,"coordinates":107},[108,109],-96.80667,32.78306,{"lat":109,"lon":108},{"facility":112,"status":32,"city":113,"state":104,"zip":114,"country":36,"countryCode":37,"cosmosGeoPoint":115,"geoPoint":119,"contacts":18},"NEO-811 Houston Site","Houston","77054",{"type":39,"coordinates":116},[117,118],-95.36327,29.76328,{"lat":118,"lon":117},{"facility":121,"status":32,"city":122,"state":123,"zip":124,"country":36,"countryCode":37,"cosmosGeoPoint":125,"geoPoint":129,"contacts":18},"NEO-811 Virginia Site","Fairfax","Virginia","22031",{"type":39,"coordinates":126},[127,128],-77.30637,38.84622,{"lat":128,"lon":127},{"type":131,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100616025","phase-1-open-label-phase-12-study-of-neo-811-in-subjects-with-locally-advanced-or-metastatic-non-resectable-clear-cell-renal-cell-carcinoma-100616025",false,"NCT07300241","Open-Label Phase 1\u002F2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma","An Open-Label, First-in-Human, Phase 1\u002F2 Dose Escalation and Expansion Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma","Inclusion Criteria:\n\n* Subjects with locally advanced or metastatic non-resectable clear cell renal cell carcinoma (ccRCC).\n* Subjects must have progressed on or refused standard therapies.\n* Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1.\n* Estimated life expectancy, in the judgment of the Investigator, of at least 12 weeks.\n* Formalin-fixed paraffin-embedded (FFPE) tumor tissue, newly obtained or archival, is mandatory for enrollment to the study.\n* Measurable disease as defined by RECIST v1.1.\n* Adequate hematologic, hepatic, and renal function defined as:\n\n  * Hemoglobin ≥10 g\u002FdL,\n  * Absolute neutrophil count ≥1000 cells\u002FµL,\n  * Platelet count ≥100,000\u002FµL,\n  * AST and ALT ≤2.5 × ULN, or AST and ALT ≤5 × ULN for subjects with liver metastases,\n  * Total bilirubin ≤1.5 × ULN,\n  * Estimated glomerular filtration rate (eGFR) ≥60 mL\u002Fmin.\n* Subject can swallow oral medications and does not have a condition that could impair the oral bioavailability of the study drug.\n* Other inclusion criteria per protocol.\n\nExclusion Criteria:\n\n* Non-clear cell predominant RCC histologic subtypes.\n* Leptomeningeal disease or symptomatic active CNS metastases with exceptions for asymptomatic treated CNS metastases per protocol.\n* Prior or concurrent malignancies with exceptions per protocol.\n* History of hepatitis B virus (HBV), hepatitis C virus (HCV), or HIV infection.\n* Other exclusion criteria per protocol.","ALL","18 Years",{"count":142,"type":143},30,"ESTIMATED","INTERVENTIONAL",[146],"PHASE1","The NEO-811-101 study is an open-label, first-in-human, Phase 1\u002F2 dose escalation and expansion study testing NEO-811, an ARNT molecular glue degrader, in subjects with locally advanced or metastatic non-resectable clear cell renal cell carcinoma. The study will test NEO-811 initially as a monotherapy.",[149,150,151,152,153,154,155,156,157],"Clear Cell Renal Cell Carcinoma","Renal Cell Carcinoma","RCC","Clear Cell Renal Cell Carcinoma Metastatic","ccRCC","VHL-Associated Clear Cell Renal Cell Carcinoma","VHL-Associated Renal Cell Carcinoma","Kidney Cancer Metastatic","Kidney Cancers",[153,150,149,159,160],"VHL","Kidney Cancer","2026-05-29",{"date":163,"type":164},"2026-06-02","ACTUAL",{"date":166,"type":164},"2025-12-19",{"date":168,"type":143},"2027-09",{"name":5,"class":6},10]